{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T13:14:00Z","timestamp":1793106840143,"version":"4.5.0"},"reference-count":278,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100000923","name":"Australian Research Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000923","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Acta Biomaterialia"],"published-print":{"date-parts":[[2021,9]]},"DOI":"10.1016\/j.actbio.2021.06.023","type":"journal-article","created":{"date-parts":[[2021,6,18]],"date-time":"2021-06-18T03:48:54Z","timestamp":1623988134000},"page":"16-40","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":268,"special_numbering":"C","title":["From influenza to COVID-19: Lipid nanoparticle mRNA vaccines at the frontiers of infectious diseases"],"prefix":"10.1016","volume":"131","author":[{"given":"Emily H.","family":"Pilkington","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Estelle J.A.","family":"Suys","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalie L.","family":"Trevaskis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam K.","family":"Wheatley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danijela","family":"Zukancic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Azizah","family":"Algarni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hareth","family":"Al-Wassiti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas P.","family":"Davis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Colin W.","family":"Pouton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen J.","family":"Kent","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nghia P.","family":"Truong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.actbio.2021.06.023_bib0001","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1258\/jrsm.2012.12k044","article-title":"The origins of inoculation","volume":"105","author":"Boylston","year":"2012","journal-title":"J. R. Soc. Med."},{"key":"10.1016\/j.actbio.2021.06.023_bib0002","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1136\/bmj.318.7180.390","article-title":"Edward Jenner\u2019s inquiry after 200 years","volume":"318","author":"Baxby","year":"1999","journal-title":"BMJ"},{"key":"10.1016\/j.actbio.2021.06.023_bib0003","unstructured":"L. Pasteur, M\u00e9thode pour pr\u00e9venir la rage apr\u00e8s morsure, 1885."},{"key":"10.1016\/j.actbio.2021.06.023_bib0004","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1136\/adc.2006.095760","article-title":"Childhood immunisation: what is the future?","volume":"92","author":"Pollard","year":"2007","journal-title":"Arch. Dis. Child."},{"key":"10.1016\/j.actbio.2021.06.023_bib0005","doi-asserted-by":"crossref","first-page":"6707","DOI":"10.1016\/j.vaccine.2016.10.025","article-title":"Vaccine impact: benefits for human health","volume":"34","author":"Doherty","year":"2016","journal-title":"Vaccine"},{"key":"10.1016\/j.actbio.2021.06.023_bib0006","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.smim.2017.08.015","article-title":"Delivering the right message: challenges and opportunities in lipid nanoparticles-mediated modified mRNA therapeutics\u2014an innate immune system standpoint","volume":"34","author":"Granot","year":"2017","journal-title":"Semin. Immunol."},{"key":"10.1016\/j.actbio.2021.06.023_bib0007","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1089\/hum.1997.8.5-511","article-title":"Nomenclature for synthetic gene delivery systems","volume":"8","author":"Felgner","year":"1997","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.actbio.2021.06.023_bib0008","doi-asserted-by":"crossref","DOI":"10.1098\/rstb.2013.0433","article-title":"The contribution of vaccination to global health: past, present and future","volume":"369","author":"Greenwood","year":"2014","journal-title":"Philos. Trans. R. Soc. Lond., B, Biol. Sci."},{"key":"10.1016\/j.actbio.2021.06.023_bib0009","unstructured":"W. Jiskoot, G.F.A. Kersten, E. Mastrobattista, B. Slutter, Vaccines, in: D.J.A. Crommelin, R.D. Sindelar, B. Meibohm (Eds), Pharmaceutical Biotechnology, Springer Nature, 2016, pp. 381\u2013304."},{"key":"10.1016\/j.actbio.2021.06.023_bib0010","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1016\/j.ymthe.2017.03.035","article-title":"Preclinical and clinical demonstration of immunogenicity by mRNA vaccines against H10N8 and H7N9 Influenza viruses","volume":"25","author":"Bahl","year":"2017","journal-title":"Mol. Ther."},{"key":"10.1016\/j.actbio.2021.06.023_bib0011","doi-asserted-by":"crossref","first-page":"2533","DOI":"10.1097\/QAD.0000000000002026","article-title":"Thielemans, phase I clinical trial of an intranodally administered mRNA-based therapeutic vaccine against HIV-1 infection","volume":"32","author":"Leal","year":"2018","journal-title":"AIDS"},{"key":"10.1016\/j.actbio.2021.06.023_bib0012","doi-asserted-by":"crossref","first-page":"7097","DOI":"10.4049\/jimmunol.1002751","article-title":"Robust vaccine-elicited cellular immune responses in breast milk following systemic simian immunodeficiency virus DNA prime and live virus vector boost vaccination of lactating rhesus monkeys","volume":"185","author":"Wilks","year":"2010","journal-title":"J. Immunol."},{"key":"10.1016\/j.actbio.2021.06.023_bib0013","doi-asserted-by":"crossref","first-page":"359","DOI":"10.3390\/vaccines9040359","article-title":"Lipid-based nanoparticles in the clinic and clinical trials: from cancer nanomedicine to COVID-19 vaccines","volume":"9","author":"Thi","year":"2021","journal-title":"Vaccines"},{"key":"10.1016\/j.actbio.2021.06.023_bib0014","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.1126\/science.8456302","article-title":"Heterologous protection against influenza by injection of DNA encoding a viral protein","volume":"259","author":"Ulmer","year":"1993","journal-title":"Science"},{"key":"10.1016\/j.actbio.2021.06.023_bib0015","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1186\/s13567-019-0698-z","article-title":"Recent advances in delivery of veterinary DNA vaccines against avian pathogens","volume":"50","author":"Jazayeri","year":"2019","journal-title":"Vet. Res."},{"key":"10.1016\/j.actbio.2021.06.023_bib0016","doi-asserted-by":"crossref","first-page":"364","DOI":"10.18632\/oncotarget.26927","article-title":"A DNA telomerase vaccine for canine cancer immunotherapy","volume":"10","author":"Thalmensi","year":"2019","journal-title":"Oncotarget"},{"key":"10.1016\/j.actbio.2021.06.023_bib0017","doi-asserted-by":"crossref","first-page":"3361","DOI":"10.3390\/nano10020364","article-title":"Nanomedicines to deliver mRNA: state of the art and future perspectives","volume":"10","author":"G\u00f3mez-Aguado","year":"2020","journal-title":"Nanomaterials (Basel)"},{"key":"10.1016\/j.actbio.2021.06.023_bib0018","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1080\/21691401.2019.1576709","article-title":"Combined vaccines for prophylaxis of infectious conditions","volume":"47","author":"Shende","year":"2019","journal-title":"Artif. Cells Nanomed. Biotechnol."},{"key":"10.1016\/j.actbio.2021.06.023_bib0019","doi-asserted-by":"crossref","first-page":"594","DOI":"10.3389\/fimmu.2019.00594","article-title":"Advances in mRNA vaccines for infectious diseases","volume":"10","author":"Zhang","year":"2019","journal-title":"Front. Immunol."},{"key":"10.1016\/j.actbio.2021.06.023_bib0020","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1186\/s12967-019-1804-8","article-title":"How mRNA therapeutics are entering the monoclonal antibody field","volume":"17","author":"Van Hoecke","year":"2019","journal-title":"J. Trans. Med."},{"key":"10.1016\/j.actbio.2021.06.023_bib0021","doi-asserted-by":"crossref","first-page":"1963","DOI":"10.3389\/fimmu.2018.01963","article-title":"New vaccine technologies to combat outbreak situations","volume":"9","author":"Rauch","year":"2018","journal-title":"Front. Immunol."},{"key":"10.1016\/j.actbio.2021.06.023_bib0022","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1016\/j.drudis.2019.12.003","article-title":"Comparison of DNA and mRNA vaccines against cancer","volume":"25","author":"Jahanafrooz","year":"2020","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.actbio.2021.06.023_bib0023","doi-asserted-by":"crossref","first-page":"675","DOI":"10.2144\/000112593","article-title":"Long-term storage of DNA-free RNA for use in vaccine studies","volume":"43","author":"Jones","year":"2007","journal-title":"BioTechniques"},{"key":"10.1016\/j.actbio.2021.06.023_bib0024","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.molmed.2019.10.002","article-title":"Tailoring mRNA vaccine to balance innate\/adaptive immune response","volume":"26","author":"Linares-Fern\u00e1ndez","year":"2020","journal-title":"Trends Mol. Med."},{"key":"10.1016\/j.actbio.2021.06.023_bib0025","first-page":"564","article-title":"Advances in mRNA vaccines for infectious diseases","volume":"10","author":"Zhang","year":"2019","journal-title":"Front. Immunol."},{"key":"10.1016\/j.actbio.2021.06.023_bib0026","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/j.coi.2011.03.007","article-title":"Tumor vaccination using messenger RNA: prospects of a future therapy","volume":"23","author":"Kreiter","year":"2011","journal-title":"Curr. Opin. Immunol."},{"key":"10.1016\/j.actbio.2021.06.023_bib0027","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1038\/mt.2012.202","article-title":"Type I IFN counteracts the induction of antigen-specific immune responses by lipid-based delivery of mRNA vaccines","volume":"21","author":"Pollard","year":"2013","journal-title":"Mol. Ther."},{"key":"10.1016\/j.actbio.2021.06.023_bib0028","doi-asserted-by":"crossref","first-page":"4414","DOI":"10.1016\/j.vaccine.2012.04.060","article-title":"RNA-based vaccines","volume":"30","author":"Ulmer","year":"2012","journal-title":"Vaccine"},{"key":"10.1016\/j.actbio.2021.06.023_bib0029","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1038\/nrd4278","article-title":"mRNA-based therapeutics \u2014 developing a new class of drugs","volume":"13","author":"Sahin","year":"2014","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.actbio.2021.06.023_bib0030","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1126\/science.aar7112","article-title":"Personalized vaccines for cancer immunotherapy","volume":"359","author":"Sahin","year":"2018","journal-title":"Science"},{"key":"10.1016\/j.actbio.2021.06.023_bib0031","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1016\/S0140-6736(17)31665-3","article-title":"Safety and immunogenicity of a mRNA rabies vaccine in healthy adults: an open-label, non-randomised, prospective, first-in-human phase 1 clinical trial","volume":"390","author":"Alberer","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.actbio.2021.06.023_bib0032","series-title":"Vaccines For Cancer Immunotherapy: An Evidence-Based Review on Current Status and Future Perspectives","first-page":"129","article-title":"Vaccines for cancer immunotherapy","author":"Valilou","year":"2018"},{"key":"10.1016\/j.actbio.2021.06.023_bib0033","doi-asserted-by":"crossref","first-page":"2601","DOI":"10.1038\/s41467-020-16505-0","article-title":"Immunogenicity of a DNA vaccine candidate for COVID-19","volume":"11","author":"Smith","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.actbio.2021.06.023_bib0034","doi-asserted-by":"crossref","first-page":"37","DOI":"10.3390\/vaccines7020037","article-title":"A comparison of plasmid DNA and mRNA as vaccine technologies","volume":"7","author":"Liu","year":"2019","journal-title":"Vaccines"},{"key":"10.1016\/j.actbio.2021.06.023_bib0035","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1186\/s13046-019-1154-7","article-title":"Cancer DNA vaccines: current preclinical and clinical developments and future perspectives","volume":"38","author":"Lopes","year":"2019","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.actbio.2021.06.023_bib0036","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1016\/j.ymthe.2019.03.002","article-title":"mRNA: a novel avenue to antibody therapy?","volume":"27","author":"Schlake","year":"2019","journal-title":"Mol. Ther."},{"key":"10.1016\/j.actbio.2021.06.023_bib0037","unstructured":"Moderna Inc, Moderna announces longer shelf life for its COVID-19 vaccine candidate at refrigerated temperatures, https:\/\/investors.modernatx.com\/news-releases\/news-release-details\/moderna-announces-longer-shelf-life-its-covid-19-vaccine, 2020 (accessed 13 May 2021)."},{"key":"10.1016\/j.actbio.2021.06.023_bib0038","unstructured":"BioNTech SE, Pfizer Inc, Pfizer and Biontech Conclude Phase 3 Study of Covid-19 Vaccine Candidate, Meeting All Primary Efficacy Endpoints, https:\/\/www.pfizer.com\/news\/press-release\/press-release-detail\/pfizer-and-biontech-conclude-phase-3-study-covid-19-vaccine, 2020 (Accessed 13 May 2021)."},{"key":"10.1016\/j.actbio.2021.06.023_bib0039","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1038\/nrd.2017.243","article-title":"mRNA vaccines \u2014 a new era in vaccinology","volume":"17","author":"Pardi","year":"2018","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.actbio.2021.06.023_bib0040","doi-asserted-by":"crossref","DOI":"10.1016\/j.nantod.2019.100766","article-title":"Three decades of messenger RNA vaccine development","volume":"28","author":"Verbeke","year":"2019","journal-title":"Nano Today"},{"key":"10.1016\/j.actbio.2021.06.023_bib0041","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1038\/nrd.2018.132","article-title":"An RNA toolbox for cancer immunotherapy","volume":"17","author":"Pastor","year":"2018","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.actbio.2021.06.023_bib0042","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1126\/science.1690918","article-title":"Direct gene transfer into mouse muscle in vivo","volume":"247","author":"Wolff","year":"1990","journal-title":"Science"},{"key":"10.1016\/j.actbio.2021.06.023_bib0043","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1002\/eji.1830230749","article-title":"Induction of virus-specific cytotoxic T lymphocytes in vivo by liposome-entrapped mRNA","volume":"23","author":"Martinon","year":"1993","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.actbio.2021.06.023_bib0044","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1182\/blood.V66.5.1149.1149","article-title":"Half-lives of beta and gamma globin messenger RNAs and of protein synthetic capacity in cultured human reticulocytes","volume":"66","author":"Ross","year":"1985","journal-title":"Blood"},{"key":"10.1016\/j.actbio.2021.06.023_bib0045","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1016\/0092-8674(76)90217-8","article-title":"Biosynthesis and stability of globin mRNA in cultured erythroleukemic friend cells","volume":"8","author":"Aviv","year":"1976","journal-title":"Cell"},{"key":"10.1016\/j.actbio.2021.06.023_bib0046","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1038\/nature18300","article-title":"Systemic RNA delivery to dendritic cells exploits antiviral defence for cancer immunotherapy","volume":"534","author":"Kranz","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.actbio.2021.06.023_bib0047","doi-asserted-by":"crossref","first-page":"2424","DOI":"10.1021\/acs.biochem.7b01162","article-title":"P-bodies: composition, properties, and functions","volume":"57","author":"Luo","year":"2018","journal-title":"Biochemistry"},{"key":"10.1016\/j.actbio.2021.06.023_bib0048","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1261\/rna.069286.118","article-title":"Segmented poly(A) tails significantly reduce recombination of plasmid DNA without affecting mRNA translation efficiency or half-life","volume":"25","author":"Trepotec","year":"2019","journal-title":"RNA"},{"key":"10.1016\/j.actbio.2021.06.023_bib0049","doi-asserted-by":"crossref","first-page":"E2106","DOI":"10.1073\/pnas.1612444114","article-title":"Structure of human IFIT1 with capped RNA reveals adaptable mRNA binding and mechanisms for sensing N1 and N2 ribose 2\u2032-O methylations","volume":"114","author":"Abbas","year":"2017","journal-title":"Proc. Natl. Acad. Sci. U.S.A.,"},{"key":"10.1016\/j.actbio.2021.06.023_bib0050","doi-asserted-by":"crossref","first-page":"12025","DOI":"10.1073\/pnas.1412842111","article-title":"Broad and adaptable RNA structure recognition by the human interferon-induced tetratricopeptide repeat protein IFIT5","volume":"111","author":"Katibah","year":"2014","journal-title":"Proc. Natl. Acad. Sci. U.S.A.,"},{"key":"10.1016\/j.actbio.2021.06.023_bib0051","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.immuni.2015.06.015","article-title":"A conserved histidine in the RNA sensor RIG-I controls immune tolerance to N1-20O-methylated Self RNA","volume":"43","author":"Schuberth-Wagner","year":"2015","journal-title":"Immunity"},{"key":"10.1016\/j.actbio.2021.06.023_bib0052","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1016\/j.omtn.2018.06.010","article-title":"Uridine depletion and chemical modification increase Cas9 mRNA activity and reduce immunogenicity without HPLC purification","volume":"12","author":"Vaidyanathan","year":"2018","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.actbio.2021.06.023_bib0053","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1038\/nrm.2017.91","article-title":"Codon optimality, bias and usage in translation and mRNA decay","volume":"19","author":"Hanson","year":"2018","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.actbio.2021.06.023_bib0054","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1038\/mt.2015.103","article-title":"Sequence-engineered mRNA without chemical nucleoside modifications enables an effective protein therapy in large animals","volume":"23","author":"Thess","year":"2015","journal-title":"Mol. Ther."},{"key":"10.1016\/j.actbio.2021.06.023_bib0055","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1126\/science.1170160","article-title":"Coding-sequence determinants of gene expression in Escherichia coli","volume":"324","author":"Kudla","year":"2009","journal-title":"Science"},{"key":"10.1016\/j.actbio.2021.06.023_bib0056","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1016\/j.molmed.2014.09.003","article-title":"A critical analysis of codon optimization in human therapeutics","volume":"20","author":"Mauro","year":"2014","journal-title":"Trends Mol. Med."},{"key":"10.1016\/j.actbio.2021.06.023_bib0057","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1093\/molbev\/mss273","article-title":"Good codons, bad transcript: large reductions in gene expression and fitness arising from synonymous mutations in a key enzyme","volume":"30","author":"Agashe","year":"2013","journal-title":"Mol. Biol. Evol."},{"key":"10.1016\/j.actbio.2021.06.023_bib0058","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1016\/j.jmb.2012.06.010","article-title":"Silent substitutions predictably alter translation elongation rates and protein folding efficiencies","volume":"422","author":"Spencer","year":"2012","journal-title":"J. Mol. Biol."},{"key":"10.1016\/j.actbio.2021.06.023_bib0059","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.4049\/jimmunol.1601129","article-title":"A new RNA-based adjuvant enhances virus-specific vaccine responses by locally triggering TLR- and RLH-dependent effects","volume":"198","author":"Ziegler","year":"2017","journal-title":"J. Immunol."},{"key":"10.1016\/j.actbio.2021.06.023_bib0060","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1002\/ijc.29402","article-title":"A novel RNA-based adjuvant combines strong immunostimulatory capacities with a favorable safety profile","volume":"137","author":"Heidenreich","year":"2015","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.actbio.2021.06.023_bib0061","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1016\/j.vaccine.2019.02.024","article-title":"RNA-based adjuvant CV8102 enhances the immunogenicity of a licensed rabies vaccine in a first-in-human trial","volume":"37","author":"Doener","year":"2019","journal-title":"Vaccine"},{"key":"10.1016\/j.actbio.2021.06.023_bib0062","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1007\/s00262-019-02315-x","article-title":"A phase I\/IIa study of the mRNA-based cancer immunotherapy CV9201 in patients with stage IIIB\/IV non-small cell lung cancer","volume":"68","author":"Sebastian","year":"2019","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.actbio.2021.06.023_bib0063","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.immuni.2005.06.008","article-title":"Suppression of RNA recognition by toll-like receptors: the impact of nucleoside modification and the evolutionary origin of RNA","volume":"23","author":"Karik\u00f3","year":"2005","journal-title":"Immunity"},{"key":"10.1016\/j.actbio.2021.06.023_bib0064","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1261\/rna.1007408","article-title":"Nucleoside modifications modulate activation of the protein kinase PKR in an RNA structure-specific manner","volume":"14","author":"Nallagatla","year":"2008","journal-title":"RNA"},{"key":"10.1016\/j.actbio.2021.06.023_bib0065","doi-asserted-by":"crossref","first-page":"5884","DOI":"10.1093\/nar\/gkq347","article-title":"Incorporation of pseudouridine into mRNA enhances translation by diminishing PKR activation","volume":"38","author":"Anderson","year":"2010","journal-title":"Nucleic. Acids. Res."},{"key":"10.1016\/j.actbio.2021.06.023_bib0066","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1038\/mt.2012.7","article-title":"Increased erythropoiesis in mice injected with submicrogram quantities of pseudouridine-containing mRNA encoding erythropoietin","volume":"20","author":"Karik\u00f3","year":"2012","journal-title":"Mol. Ther."},{"key":"10.1016\/j.actbio.2021.06.023_bib0067","doi-asserted-by":"crossref","first-page":"2012","DOI":"10.1038\/mt.2016.161","article-title":"Type I interferons interfere with the capacity of mRNA lipoplex vaccines to elicit cytolytic T cell responses","volume":"24","author":"De Beuckelaer","year":"2016","journal-title":"Mol. Ther."},{"key":"10.1016\/j.actbio.2021.06.023_bib0068","doi-asserted-by":"crossref","first-page":"609","DOI":"10.3389\/fimmu.2016.00609","article-title":"Type-I Interferon Responses: from Friend to Foe in the Battle against Chronic Viral Infection","volume":"7","author":"Murira","year":"2016","journal-title":"Front. Immunol."},{"key":"10.1016\/j.actbio.2021.06.023_bib0069","doi-asserted-by":"crossref","first-page":"e142","DOI":"10.1093\/nar\/gkr695","article-title":"Generating the optimal mRNA for therapy: HPLC purification eliminates immune activation and improves translation of nucleoside-modified, protein-encoding mRNA","volume":"39","author":"Karik\u00f3","year":"2011","journal-title":"Nucleic. Acids. Res."},{"key":"10.1016\/j.actbio.2021.06.023_bib0070","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.biomaterials.2016.09.006","article-title":"Efficacy and immunogenicity of unmodified and pseudouridine-modified mRNA delivered systemically with lipid nanoparticles in vivo","volume":"109","author":"Kauffman","year":"2016","journal-title":"Biomaterials"},{"key":"10.1016\/j.actbio.2021.06.023_bib0071","doi-asserted-by":"crossref","first-page":"3361","DOI":"10.1038\/s41467-018-05482-0","article-title":"Nucleoside-modified mRNA immunization elicits influenza virus hemagglutinin stalk-specific antibodies","volume":"9","author":"Pardi","year":"2018","journal-title":"Nat. Commun."},{"key":"10.1016\/j.actbio.2021.06.023_bib0072","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.omtn.2019.02.018","article-title":"A facile method for the removal of dsRNA contaminant from in vitro-transcribed mRNA","volume":"15","author":"Baiersd\u00f6rfer","year":"2019","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.actbio.2021.06.023_bib0073","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1016\/j.ymthe.2017.11.017","article-title":"Self-amplifying RNA vaccines give equivalent protection against influenza to mRNA vaccines but at much lower doses","volume":"26","author":"Vogel","year":"2018","journal-title":"Mol. Ther."},{"key":"10.1016\/j.actbio.2021.06.023_bib0074","doi-asserted-by":"crossref","first-page":"14604","DOI":"10.1073\/pnas.1209367109","article-title":"Nonviral delivery of self-amplifying RNA vaccines","volume":"109","author":"Geall","year":"2012","journal-title":"Proc. Natl. Acad. Sci. U.S.A.,"},{"key":"10.1016\/j.actbio.2021.06.023_bib0075","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1093\/nar\/23.9.1495","article-title":"A Sindbis virus mRNA polynucleotide vector achieves prolonged and high level heterologous gene expression in vivo","volume":"23","author":"Johanning","year":"1995","journal-title":"Nucleic. Acids. Res."},{"key":"10.1016\/j.actbio.2021.06.023_bib0076","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1128\/JVI.01786-15","article-title":"Induction of broad-based immunity and protective efficacy by self-amplifying mRNA vaccines encoding influenza virus hemagglutinin","volume":"90","author":"Brazzoli","year":"2016","journal-title":"J. Virol."},{"key":"10.1016\/j.actbio.2021.06.023_bib0077","doi-asserted-by":"crossref","first-page":"4012","DOI":"10.4049\/jimmunol.1601877","article-title":"Induction of an IFN-mediated antiviral response by a self-amplifying RNA vaccine: implications for vaccine design","volume":"198","author":"Pepini","year":"2017","journal-title":"J. Immunol."},{"key":"10.1016\/j.actbio.2021.06.023_bib0078","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.molmed.2017.01.006","article-title":"Type I interferons modulate CD8(+) T cell immunity to mRNA vaccines","volume":"23","author":"De Beuckelaer","year":"2017","journal-title":"Trends Mol. Med."},{"key":"10.1016\/j.actbio.2021.06.023_bib0079","doi-asserted-by":"crossref","first-page":"e142","DOI":"10.1093\/nar\/gkr695","article-title":"Generating the optimal mRNA for therapy: HPLC purification eliminates immune activation and improves translation of nucleoside-modified, protein-encoding mRNA","volume":"39","author":"Karik\u00f3","year":"2011","journal-title":"Nucleic. Acids. Res."},{"key":"10.1016\/j.actbio.2021.06.023_bib0080","doi-asserted-by":"crossref","first-page":"5204","DOI":"10.1038\/s41467-020-19025-z","article-title":"Structural analysis reveals TLR7 dynamics underlying antagonism","volume":"11","author":"Tojo","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.actbio.2021.06.023_bib0081","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1038\/nsmb.2943","article-title":"Toll-like receptor 8 senses degradation products of single-stranded RNA","volume":"22","author":"Tanji","year":"2015","journal-title":"Nat. Struct. Mol. Biol."},{"key":"10.1016\/j.actbio.2021.06.023_bib0082","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.4049\/jimmunol.161.3.1313","article-title":"Dendritic cells interact directly with naive B lymphocytes to transfer antigen and initiate class switching in a primary T-dependent response","volume":"161","author":"Wykes","year":"1998","journal-title":"J. Immunol."},{"key":"10.1016\/j.actbio.2021.06.023_bib0083","doi-asserted-by":"crossref","first-page":"E6639","DOI":"10.1073\/pnas.1606050113","article-title":"Sustained antigen availability during germinal center initiation enhances antibody responses to vaccination","volume":"113","author":"Tam","year":"2016","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.actbio.2021.06.023_bib0084","doi-asserted-by":"crossref","DOI":"10.1002\/adhm.202002142","article-title":"Hemagglutinin functionalized liposomal vaccines enhance germinal center and follicular helper T cell immunity","volume":"10","author":"Vu","year":"2021","journal-title":"Adv. Healthcare Mater."},{"key":"10.1016\/j.actbio.2021.06.023_bib0085","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1016\/j.vaccine.2012.12.027","article-title":"RNA pulsed dendritic cells: an approach for cancer immunotherapy","volume":"31","author":"Garg","year":"2013","journal-title":"Vaccine"},{"key":"10.1016\/j.actbio.2021.06.023_bib0086","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1586\/14760584.2014.957684","article-title":"mRNA-based dendritic cell vaccines","volume":"14","author":"Benteyn","year":"2015","journal-title":"Expert Rev. Vaccines"},{"key":"10.1016\/j.actbio.2021.06.023_bib0087","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fphys.2015.00001","article-title":"Macropinocytosis in phagocytes: regulation of MHC class-II-restricted antigen presentation in dendritic cells","volume":"6","author":"Liu","year":"2015","journal-title":"Front. Physiol."},{"key":"10.1016\/j.actbio.2021.06.023_bib0088","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1172\/JCI0214364","article-title":"Autologous dendritic cells transfected with prostate-specific antigen RNA stimulate CTL responses against metastatic prostate tumors","volume":"109","author":"Heiser","year":"2002","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.actbio.2021.06.023_bib0089","doi-asserted-by":"crossref","first-page":"265","DOI":"10.4161\/hv.22661","article-title":"mRNA: from a chemical blueprint for protein production to an off-the-shelf therapeutic","volume":"9","author":"Van Lint","year":"2013","journal-title":"Hum. Vaccin. Immunother."},{"key":"10.1016\/j.actbio.2021.06.023_bib0090","doi-asserted-by":"crossref","first-page":"78","DOI":"10.3389\/fimmu.2014.00078","article-title":"Dendritic cell-based approaches in the fight against diseases","volume":"5","author":"Freitas-Silva","year":"2014","journal-title":"Front. Immunol."},{"key":"10.1016\/j.actbio.2021.06.023_bib0091","first-page":"1397","article-title":"Characterization of a messenger RNA polynucleotide vaccine vector","volume":"55","author":"Conry","year":"1995","journal-title":"Cancer Res."},{"key":"10.1016\/j.actbio.2021.06.023_bib0092","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.4161\/rna.22269","article-title":"Developing mRNA-vaccine technologies","volume":"9","author":"Schlake","year":"2012","journal-title":"RNA Biol."},{"key":"10.1016\/j.actbio.2021.06.023_bib0093","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1038\/sj.gt.3302964","article-title":"Spontaneous cellular uptake of exogenous messenger RNA in vivo is nucleic acid-specific, saturable and ion dependent","volume":"14","author":"Probst","year":"2007","journal-title":"Gene Ther."},{"key":"10.1016\/j.actbio.2021.06.023_bib0094","doi-asserted-by":"crossref","first-page":"102","DOI":"10.3390\/pharmaceutics12020102","article-title":"Opportunities and challenges in the delivery of mRNA-based vaccines","volume":"12","author":"Wadhwa","year":"2020","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.actbio.2021.06.023_bib0095","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/j.ymthe.2019.01.020","article-title":"mRNA as a transformative technology for vaccine development to control infectious diseases","volume":"27","author":"Maruggi","year":"2019","journal-title":"Mol. Ther."},{"key":"10.1016\/j.actbio.2021.06.023_bib0096","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.coi.2020.01.008","article-title":"Recent advances in mRNA vaccine technology","volume":"65","author":"Pardi","year":"2020","journal-title":"Curr. Opin. Immunol."},{"key":"10.1016\/j.actbio.2021.06.023_bib0097","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1016\/j.cell.2017.02.017","article-title":"Modified mRNA vaccines protect against Zika virus infection","volume":"168","author":"Richner","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.actbio.2021.06.023_bib0098","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.jviromet.2007.04.013","article-title":"Selection of an optimal RNA transfection reagent and comparison to electroporation for the delivery of viral RNA","volume":"145","author":"Gonzalez","year":"2007","journal-title":"J. Virol. Methods"},{"key":"10.1016\/j.actbio.2021.06.023_bib0099","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/j.actbio.2018.05.016","article-title":"Fluorescence correlation spectroscopy to find the critical balance between extracellular association and intracellular dissociation of mRNA complexes","volume":"75","author":"Zhang","year":"2018","journal-title":"Acta Biomater."},{"key":"10.1016\/j.actbio.2021.06.023_bib0100","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.1016\/j.drudis.2018.05.033","article-title":"Lipid\u2013polymer hybrid nanocarrier-mediated cancer therapeutics: current status and future directions","volume":"23","author":"Garg","year":"2018","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.actbio.2021.06.023_bib0101","doi-asserted-by":"crossref","first-page":"406","DOI":"10.3390\/nano11020406","article-title":"Transdermal immunization of elastic liposome-laden recombinant chimeric fusion protein of P. falciparum (PfMSP-Fu24) mounts protective immune response","volume":"11","author":"Chaudhari","year":"2021","journal-title":"Nanomaterials (Basel)"},{"key":"10.1016\/j.actbio.2021.06.023_bib0102","doi-asserted-by":"crossref","first-page":"2043","DOI":"10.1016\/j.nano.2016.05.008","article-title":"The ligand(s) anchored lipobrid nanoconstruct mediated delivery of methotrexate: an effective approach in breast cancer therapeutics","volume":"12","author":"Garg","year":"2016","journal-title":"Nanomedicine"},{"key":"10.1016\/j.actbio.2021.06.023_bib0103","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.ijpharm.2015.12.061","article-title":"Nanostructured lipid carrier mediates effective delivery of methotrexate to induce apoptosis of rheumatoid arthritis via NF-\u03baB and FOXO1","volume":"499","author":"Garg","year":"2016","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.actbio.2021.06.023_bib0104","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1007\/s12272-018-1060-0","article-title":"Soft- and hard-lipid nanoparticles: a novel approach to lymphatic drug delivery","volume":"41","author":"Jeong","year":"2018","journal-title":"Arch. Pharm. Res."},{"key":"10.1016\/j.actbio.2021.06.023_bib0105","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1038\/s41598-017-18573-7","article-title":"Use of nanoparticle concentration as a tool to understand the structural properties of colloids","volume":"8","author":"Ribeiro","year":"2018","journal-title":"Sci. Rep."},{"key":"10.1016\/j.actbio.2021.06.023_bib0106","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/S0005-2736(97)00126-0","article-title":"Toxicity and immunomodulatory activity of liposomal vectors formulated with cationic lipids toward immune effector cells","volume":"1329","author":"Filion","year":"1997","journal-title":"BBA Biomembranes"},{"key":"10.1016\/j.actbio.2021.06.023_bib0107","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1023\/A:1018932714745","article-title":"Comparison of cell proliferation and toxicity assays using two cationic liposomes","volume":"11","author":"Lappalainen","year":"1994","journal-title":"Pharm. Res."},{"key":"10.1016\/j.actbio.2021.06.023_bib0108","doi-asserted-by":"crossref","DOI":"10.1002\/smtd.201700375","article-title":"State-of-the-art design and rapid-mixing production techniques of lipid nanoparticles for nucleic acid delivery","volume":"2","author":"Evers","year":"2018","journal-title":"Small Methods"},{"key":"10.1016\/j.actbio.2021.06.023_bib0109","doi-asserted-by":"crossref","first-page":"2073","DOI":"10.1021\/acs.jpcb.7b10795","article-title":"Structure of lipid nanoparticles containing siRNA or mRNA by dynamic nuclear polarization-enhanced NMR spectroscopy","volume":"122","author":"Viger-Gravel","year":"2018","journal-title":"J. Phys. Chem. B"},{"key":"10.1016\/j.actbio.2021.06.023_bib0110","doi-asserted-by":"crossref","first-page":"4543","DOI":"10.1021\/acs.nanolett.0c01386","article-title":"Deconvoluting lipid nanoparticle structure for messenger RNA delivery","volume":"20","author":"Eygeris","year":"2020","journal-title":"Nano Lett."},{"key":"10.1016\/j.actbio.2021.06.023_bib0111","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1038\/s41467-020-14527-2","article-title":"Naturally-occurring cholesterol analogues in lipid nanoparticles induce polymorphic shape and enhance intracellular delivery of mRNA","volume":"11","author":"Patel","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.actbio.2021.06.023_bib0112","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1126\/science.1066238","article-title":"Chaotic mixer for microchannels","volume":"295","author":"Stroock","year":"2002","journal-title":"Science"},{"key":"10.1016\/j.actbio.2021.06.023_bib0113","doi-asserted-by":"crossref","first-page":"23959","DOI":"10.1039\/D0NR06816K","article-title":"Spontaneous, solvent-free entrapment of siRNA within lipid nanoparticles","volume":"12","author":"Kulkarni","year":"2020","journal-title":"Nanoscale"},{"key":"10.1016\/j.actbio.2021.06.023_bib0114","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.3390\/pharmaceutics12111095","article-title":"Manufacturing considerations for the development of lipid nanoparticles using microfluidics","volume":"12","author":"Roces","year":"2020","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.actbio.2021.06.023_bib0115","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.actbio.2018.09.047","article-title":"Size-controlled lipid nanoparticle production using turbulent mixing to enhance oral DNA delivery","volume":"81","author":"He","year":"2018","journal-title":"Acta Biomater."},{"key":"10.1016\/j.actbio.2021.06.023_bib0116","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1016\/j.actbio.2020.12.024","article-title":"Preparation of cetyl palmitate-based PEGylated solid lipid nanoparticles by microfluidic technique","volume":"121","author":"Arduino","year":"2020","journal-title":"Acta Biomater."},{"key":"10.1016\/j.actbio.2021.06.023_bib0117","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1716153","article-title":"Patisiran, an RNAi Therapeutic, for hereditary transthyretin amyloidosis","volume":"379","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.actbio.2021.06.023_bib0118","doi-asserted-by":"crossref","first-page":"7300","DOI":"10.1021\/acs.nanolett.5b02497","article-title":"Optimization of lipid nanoparticle formulations for mrna delivery in vivo with fractional factorial and definitive screening designs","volume":"15","author":"Kauffman","year":"2015","journal-title":"Nano Lett."},{"key":"10.1016\/j.actbio.2021.06.023_bib0119","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1016\/j.jconrel.2019.10.028","article-title":"Ionizable lipid nanoparticles encapsulating barcoded mRNA for accelerated in vivo delivery screening","volume":"316","author":"Guimaraes","year":"2019","journal-title":"J. Control. Release"},{"key":"10.1016\/j.actbio.2021.06.023_bib0120","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.actbio.2020.03.020","article-title":"Advancements in prophylactic and therapeutic nanovaccines","volume":"108","author":"Bhardwaj","year":"2020","journal-title":"Acta Biomater."},{"key":"10.1016\/j.actbio.2021.06.023_bib0121","article-title":"Cellular interactions of liposomes and PISA nanoparticles during human blood flow in a microvascular network","volume":"16","author":"Vu","year":"2020","journal-title":"Small"},{"key":"10.1016\/j.actbio.2021.06.023_bib0122","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.addr.2012.09.037","article-title":"Liposomal drug delivery systems: from concept to clinical applications","volume":"65","author":"Allen","year":"2013","journal-title":"Adv. Drug. Deliv. Rev."},{"key":"10.1016\/j.actbio.2021.06.023_bib0123","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1038\/sj.gt.3301506","article-title":"On the mechanism whereby cationic lipids promote intracellular delivery of polynucleic acids","volume":"8","author":"Hafez","year":"2001","journal-title":"Gene Ther."},{"key":"10.1016\/j.actbio.2021.06.023_bib0124","doi-asserted-by":"crossref","first-page":"10431","DOI":"10.1016\/S0021-9258(19)70482-7","article-title":"Introduction of liposome-encapsulated SV40 DNA into cells","volume":"255","author":"Fraley","year":"1980","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.actbio.2021.06.023_bib0125","doi-asserted-by":"crossref","first-page":"6978","DOI":"10.1021\/bi00527a031","article-title":"Liposome-mediated delivery of deoxyribonucleic acid to cells: enhanced efficiency of delivery by changes in lipid composition and incubation conditions","volume":"20","author":"Fraley","year":"1981","journal-title":"Biochemistry"},{"key":"10.1016\/j.actbio.2021.06.023_bib0126","doi-asserted-by":"crossref","first-page":"8529","DOI":"10.1002\/anie.201203263","article-title":"Maximizing the potency of siRNA lipid nanoparticles for hepatic gene silencing in vivo","volume":"51","author":"Jayaraman","year":"2012","journal-title":"Angew. Chem. Int. Ed."},{"key":"10.1016\/j.actbio.2021.06.023_bib0127","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1038\/nbt.1602","article-title":"Rational design of cationic lipids for siRNA delivery","volume":"28","author":"Semple","year":"2010","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.actbio.2021.06.023_bib0128","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/j.jconrel.2005.06.014","article-title":"Cationic lipid saturation influences intracellular delivery of encapsulated nucleic acids","volume":"107","author":"Heyes","year":"2005","journal-title":"J. Control. Release"},{"key":"10.1016\/j.actbio.2021.06.023_bib0129","doi-asserted-by":"crossref","first-page":"20019","DOI":"10.1038\/srep20019","article-title":"Intrathecal delivery of frataxin mRNA encapsulated in lipid nanoparticles to dorsal root ganglia as a potential therapeutic for Friedreich\u2019s ataxia","volume":"6","author":"Nabhan","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.actbio.2021.06.023_bib0130","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1038\/mt.2013.124","article-title":"Biodegradable lipids enabling rapidly eliminated lipid nanoparticles for systemic delivery of RNAi therapeutics","volume":"21","author":"Maier","year":"2013","journal-title":"Mol. Ther."},{"key":"10.1016\/j.actbio.2021.06.023_bib0131","doi-asserted-by":"crossref","first-page":"2939","DOI":"10.1002\/adma.201505822","article-title":"Bioinspired alkenyl amino alcohol ionizable lipid materials for highly potent in vivo mRNA delivery","volume":"28","author":"Fenton","year":"2016","journal-title":"Adv. Mater."},{"key":"10.1016\/j.actbio.2021.06.023_bib0132","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.actbio.2019.11.022","article-title":"Hydrophobic scaffolds of pH-sensitive cationic lipids contribute to miscibility with phospholipids and improve the efficiency of delivering short interfering RNA by small-sized lipid nanoparticles","volume":"102","author":"Sato","year":"2020","journal-title":"Acta Biomater."},{"key":"10.1016\/j.actbio.2021.06.023_bib0133","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/S0005-2736(00)00343-6","article-title":"Efficient encapsulation of antisense oligonucleotides in lipid vesicles using ionizable aminolipids: formation of novel small multilamellar vesicle structures","volume":"1510","author":"Semple","year":"2001","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.actbio.2021.06.023_bib0134","doi-asserted-by":"crossref","first-page":"1688","DOI":"10.1038\/mt.2011.141","article-title":"Synergistic silencing: combinations of lipid-like materials for efficacious siRNA delivery","volume":"19","author":"Whitehead","year":"2011","journal-title":"Mol. Ther."},{"key":"10.1016\/j.actbio.2021.06.023_bib0135","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1038\/nbt1402","article-title":"A combinatorial library of lipid-like materials for delivery of RNAi therapeutics","volume":"26","author":"Akinc","year":"2008","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.actbio.2021.06.023_bib0136","doi-asserted-by":"crossref","first-page":"1864","DOI":"10.1073\/pnas.0910603106","article-title":"Lipid-like materials for low-dose, in vivo gene silencing","volume":"107","author":"Love","year":"2010","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.actbio.2021.06.023_bib0137","doi-asserted-by":"crossref","DOI":"10.1002\/adhm.201901487","article-title":"Lipid-modified aminoglycosides for mRNA delivery to the liver","volume":"9","author":"Yu","year":"2020","journal-title":"Adv. Healthcare Mater."},{"key":"10.1016\/j.actbio.2021.06.023_bib0138","doi-asserted-by":"crossref","first-page":"7413","DOI":"10.1073\/pnas.84.21.7413","article-title":"Lipofection: a highly efficient, lipid-mediated DNA-transfection procedure","volume":"84","author":"Felgner","year":"1987","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.actbio.2021.06.023_bib0139","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/S0169-409X(01)00103-X","article-title":"Roles of lipid polymorphism in intracellular delivery","volume":"47","author":"Hafez","year":"2001","journal-title":"Adv. Drug. Deliv. Rev."},{"key":"10.1016\/j.actbio.2021.06.023_bib0140","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/0005-2736(95)80016-9","article-title":"The role of dioleoyl phosphatidylethanolamine in cationic liposome mediated gene transfer","volume":"1235","author":"Farhood","year":"1995","journal-title":"BBA Biomembranes"},{"key":"10.1016\/j.actbio.2021.06.023_bib0141","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/S0005-2736(99)00059-0","article-title":"Stabilized plasmid-lipid particles: factors influencing plasmid entrapment and transfection properties","volume":"1419","author":"Mok","year":"1999","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.actbio.2021.06.023_bib0142","doi-asserted-by":"crossref","first-page":"3435","DOI":"10.1016\/j.biomaterials.2011.01.021","article-title":"The effect of surface charge on in vivo biodistribution of PEG-oligocholic acid based micellar nanoparticles","volume":"32","author":"Xiao","year":"2011","journal-title":"Biomaterials"},{"key":"10.1016\/j.actbio.2021.06.023_bib0143","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1038\/s41565-020-0669-6","article-title":"Selective organ targeting (SORT) nanoparticles for tissue-specific mRNA delivery and CRISPR\u2013Cas gene editing","volume":"15","author":"Cheng","year":"2020","journal-title":"Nat. Nanotechnol."},{"key":"10.1016\/j.actbio.2021.06.023_bib0144","doi-asserted-by":"crossref","first-page":"4787","DOI":"10.1021\/acsnano.8b01516","article-title":"On the formation and morphology of lipid nanoparticles containing ionizable cationic lipids and siRNA","volume":"12","author":"Kulkarni","year":"2018","journal-title":"ACS Nano"},{"key":"10.1016\/j.actbio.2021.06.023_bib0145","doi-asserted-by":"crossref","first-page":"8698","DOI":"10.1021\/acs.jpcb.5b02891","article-title":"Microfluidic mixing: a general method for encapsulating macromolecules in lipid nanoparticle systems","volume":"119","author":"Leung","year":"2015","journal-title":"J. Phys. Chem. B"},{"key":"10.1016\/j.actbio.2021.06.023_bib0146","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1016\/j.ymthe.2018.03.010","article-title":"A Novel amino lipid series for mRNA delivery: improved endosomal escape and sustained pharmacology and safety in non-human primates","volume":"26","author":"Sabnis","year":"2018","journal-title":"Mol. Ther."},{"key":"10.1016\/j.actbio.2021.06.023_bib0147","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.omtn.2019.01.013","article-title":"Optimization of lipid nanoparticles for intramuscular administration of mRNA vaccines","volume":"15","author":"Hassett","year":"2019","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.actbio.2021.06.023_bib0148","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1021\/acs.nanolett.6b03329","article-title":"Lipid nanoparticle assisted mRNA delivery for potent cancer immunotherapy","volume":"17","author":"Oberli","year":"2017","journal-title":"Nano Lett."},{"key":"10.1016\/j.actbio.2021.06.023_bib0149","doi-asserted-by":"crossref","DOI":"10.1002\/adma.201805308","article-title":"Dendrimer-based lipid nanoparticles deliver therapeutic FAH mRNA to normalize liver function and extend survival in a mouse model of hepatorenal tyrosinemia type I","volume":"30","author":"Cheng","year":"2018","journal-title":"Adv. Mater."},{"key":"10.1016\/j.actbio.2021.06.023_bib0150","doi-asserted-by":"crossref","first-page":"21733","DOI":"10.1039\/C9NR09347H","article-title":"On the role of helper lipids in lipid nanoparticle formulations of siRNA","volume":"11","author":"Kulkarni","year":"2019","journal-title":"Nanoscale"},{"key":"10.1016\/j.actbio.2021.06.023_bib0151","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1002\/anie.201610209","article-title":"Non-viral CRISPR\/Cas gene editing in vitro and in vivo enabled by synthetic nanoparticle co-delivery of Cas9 mRNA and sgRNA","volume":"56","author":"Miller","year":"2017","journal-title":"Angew. Chem. Int. Ed. Engl."},{"key":"10.1016\/j.actbio.2021.06.023_bib0152","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1038\/s41563-020-00886-0","article-title":"Membrane-destabilizing ionizable phospholipids for organ-selective mRNA delivery and CRISPR\u2013Cas gene editing","volume":"20","author":"Liu","year":"2021","journal-title":"Nat. Mater."},{"key":"10.1016\/j.actbio.2021.06.023_bib0153","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/0304-4157(76)90008-3","article-title":"The function of sterols in membranes","volume":"457","author":"Demel","year":"1976","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.actbio.2021.06.023_bib0154","doi-asserted-by":"crossref","first-page":"1886","DOI":"10.1021\/acs.biomac.5b00550","article-title":"Cholesterol modified self-assemblies and their application to nanomedicine","author":"Ercole","year":"2015","journal-title":"Biomacromolecules"},{"key":"10.1016\/j.actbio.2021.06.023_bib0155","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/0304-4165(95)00170-0","article-title":"Effects of cholesterol on the lamellar and the inverted hexagonal phases of dielaidoylphosphatidylethanolamine","volume":"1289","author":"Takahashi","year":"1996","journal-title":"BBA Gen. Subj."},{"key":"10.1016\/j.actbio.2021.06.023_bib0156","doi-asserted-by":"crossref","first-page":"E3351","DOI":"10.1073\/pnas.1720542115","article-title":"Successful reprogramming of cellular protein production through mRNA delivered by functionalized lipid nanoparticles","volume":"115","author":"Yanez Arteta","year":"2018","journal-title":"Proc. Natl Acad. Sci."},{"key":"10.1016\/j.actbio.2021.06.023_bib0157","doi-asserted-by":"crossref","first-page":"2508","DOI":"10.1529\/biophysj.106.083766","article-title":"Cubic phases in phosphatidylcholine-cholesterol mixtures: cholesterol as membrane \u201cfusogen\u201d","volume":"91","author":"Tenchov","year":"2006","journal-title":"Biophys. J."},{"key":"10.1016\/j.actbio.2021.06.023_bib0158","doi-asserted-by":"crossref","first-page":"3960","DOI":"10.1529\/biophysj.106.099234","article-title":"The condensing effect of cholesterol in lipid bilayers","volume":"92","author":"Hung","year":"2007","journal-title":"Biophys. J."},{"key":"10.1016\/j.actbio.2021.06.023_bib0159","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.1016\/j.bbamem.2012.05.017","article-title":"Transfection efficiency boost of cholesterol-containing lipoplexes","volume":"1818","author":"Pozzi","year":"2012","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.actbio.2021.06.023_bib0160","doi-asserted-by":"crossref","first-page":"2521","DOI":"10.1021\/bi950414i","article-title":"Influence of cholesterol on the association of plasma proteins with liposomes","volume":"35","author":"Semple","year":"1996","journal-title":"Biochemistry"},{"key":"10.1016\/j.actbio.2021.06.023_bib0161","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1007\/s12195-017-0489-4","article-title":"Phase-separated liposomes enhance the efficiency of macromolecular delivery to the cellular cytoplasm","volume":"10","author":"Imam","year":"2017","journal-title":"Cell. Mol. Bioeng."},{"key":"10.1016\/j.actbio.2021.06.023_bib0162","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.addr.2015.09.012","article-title":"PEGylation as a strategy for improving nanoparticle-based drug and gene delivery","volume":"99","author":"Suk","year":"2016","journal-title":"Adv. Drug. Deliv. Rev."},{"key":"10.1016\/j.actbio.2021.06.023_bib0163","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.bbamem.2005.02.001","article-title":"Stabilized plasmid-lipid particles containing PEG-diacylglycerols exhibit extended circulation lifetimes and tumor selective gene expression","volume":"1669","author":"Ambegia","year":"2005","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.actbio.2021.06.023_bib0164","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.chemphyslip.2005.02.003","article-title":"Effect of grafted PEG on liposome size and on compressibility and packing of lipid bilayer","volume":"135","author":"Garbuzenko","year":"2005","journal-title":"Chem. Phys. Lipids."},{"key":"10.1016\/j.actbio.2021.06.023_bib0165","doi-asserted-by":"crossref","first-page":"e37","DOI":"10.1038\/mtna.2012.28","article-title":"Microfluidic synthesis of highly potent limit-size lipid nanoparticles for in vivo delivery of siRNA","volume":"1","author":"Belliveau","year":"2012","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.actbio.2021.06.023_bib0166","doi-asserted-by":"crossref","first-page":"18440","DOI":"10.1021\/jp303267y","article-title":"Lipid nanoparticles containing siRNA synthesized by microfluidic mixing exhibit an electron-dense nanostructured core","volume":"116","author":"Leung","year":"2012","journal-title":"J. Phys. Chem. C"},{"key":"10.1016\/j.actbio.2021.06.023_bib0167","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1016\/j.bbamem.2006.12.013","article-title":"Influence of poly(ethylene glycol) grafting density and polymer length on liposomes: relating plasma circulation lifetimes to protein binding","volume":"1768","author":"Dos Santos","year":"2007","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.actbio.2021.06.023_bib0168","doi-asserted-by":"crossref","first-page":"E9944","DOI":"10.1073\/pnas.1811276115","article-title":"High-throughput in vivo screen of functional mRNA delivery identifies nanoparticles for endothelial cell gene editing","volume":"115","author":"Sago","year":"2018","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.actbio.2021.06.023_bib0169","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1007\/s11095-012-0874-6","article-title":"Effect of PEGylation on biodistribution and gene silencing of siRNA\/lipid nanoparticle complexes","volume":"30","author":"Bao","year":"2013","journal-title":"Pharm. Res."},{"key":"10.1016\/j.actbio.2021.06.023_bib0170","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.jconrel.2016.05.059","article-title":"Influence of particle size on the in vivo potency of lipid nanoparticle formulations of siRNA","volume":"235","author":"Chen","year":"2016","journal-title":"J. Control. Release"},{"key":"10.1016\/j.actbio.2021.06.023_bib0171","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1038\/mt.2010.85","article-title":"Targeted delivery of RNAi therapeutics with endogenous and exogenous ligand-based mechanisms","volume":"18","author":"Akinc","year":"2010","journal-title":"Mol. Ther."},{"key":"10.1016\/j.actbio.2021.06.023_bib0172","doi-asserted-by":"crossref","first-page":"e141","DOI":"10.1038\/mtna.2013.68","article-title":"RNA interference by single- and double-stranded siRNA with a DNA extension containing a 3\u2032 nuclease-resistant mini-hairpin structure","volume":"2","author":"Allison","year":"2014","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.actbio.2021.06.023_bib0173","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.jconrel.2013.07.026","article-title":"The accelerated blood clearance (ABC) phenomenon: clinical challenge and approaches to manage","volume":"172","author":"Abu Lila","year":"2013","journal-title":"J. Control. Release"},{"key":"10.1016\/j.actbio.2021.06.023_bib0174","doi-asserted-by":"crossref","first-page":"298","DOI":"10.3390\/polym12020298","article-title":"The importance of poly(ethylene glycol) alternatives for overcoming PEG immunogenicity in drug delivery and bioconjugation","volume":"12","author":"Thi","year":"2020","journal-title":"Polymers (Basel)"},{"key":"10.1016\/j.actbio.2021.06.023_bib0175","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.3390\/pharmaceutics12111068","article-title":"The importance of poly(ethylene glycol) and lipid structure in targeted gene delivery to lymph nodes by lipid nanoparticles","volume":"12","author":"Zukancic","year":"2020","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.actbio.2021.06.023_bib0176","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.addr.2013.11.009","article-title":"Cancer nanotechnology: the impact of passive and active targeting in the era of modern cancer biology","volume":"66","author":"Bertrand","year":"2014","journal-title":"Adv. Drug. Deliv. Rev."},{"key":"10.1016\/j.actbio.2021.06.023_bib0177","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1038\/nbt1340","article-title":"Renal clearance of quantum dots","volume":"25","author":"Choi","year":"2007","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.actbio.2021.06.023_bib0178","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1002\/jemt.20408","article-title":"Contribution of high-resolution correlative imaging techniques in the study of the liver sieve in three-dimensions","volume":"70","author":"Braet","year":"2007","journal-title":"Microsc. Res. Tech."},{"key":"10.1016\/j.actbio.2021.06.023_bib0179","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1146\/annurev-pharmtox-010611-134623","article-title":"Factors controlling nanoparticle pharmacokinetics: an integrated analysis and perspective","volume":"52","author":"Moghimi","year":"2012","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"10.1016\/j.actbio.2021.06.023_bib0180","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1038\/s41578-019-0110-7","article-title":"Material design for lymph node drug delivery","volume":"4","author":"Schudel","year":"2019","journal-title":"Nat. Rev. Mater."},{"key":"10.1016\/j.actbio.2021.06.023_bib0181","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1038\/s41565-020-0663-z","article-title":"Targeting immune cells within lymph nodes","volume":"15","author":"Porter","year":"2020","journal-title":"Nat. Nanotechnol."},{"key":"10.1016\/j.actbio.2021.06.023_bib0182","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1038\/s41565-020-0679-4","article-title":"Programmable multistage drug delivery to lymph nodes","volume":"15","author":"Schudel","year":"2020","journal-title":"Nat. Nanotechnol."},{"key":"10.1016\/j.actbio.2021.06.023_bib0183","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1084\/jem.192.10.1425","article-title":"Lymph-borne chemokines and other low molecular weight molecules reach high endothelial venules via specialized conduits while a functional barrier limits access to the lymphocyte microenvironments in lymph node cortex","volume":"192","author":"Gretz","year":"2000","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.actbio.2021.06.023_bib0184","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S0169-409X(01)00150-8","article-title":"The physiology of the lymphatic system","volume":"50","author":"Swartz","year":"2001","journal-title":"Adv. Drug. Deliv. Rev."},{"key":"10.1016\/j.actbio.2021.06.023_bib0185","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.addr.2020.06.019","article-title":"Controlling timing and location in vaccines","volume":"158","author":"Irvine","year":"2020","journal-title":"Adv. Drug. Deliv. Rev."},{"key":"10.1016\/j.actbio.2021.06.023_bib0186","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1146\/annurev-bioeng-101515-014413","article-title":"Implications of lymphatic transport to lymph nodes in immunity and immunotherapy","volume":"18","author":"Thomas","year":"2016","journal-title":"Annu. Rev. Biomed. Eng."},{"key":"10.1016\/j.actbio.2021.06.023_bib0187","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/j.cell.2020.06.039","article-title":"The lymphatic vasculature in the 21st century: novel functional roles in homeostasis and disease","volume":"182","author":"Oliver","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.actbio.2021.06.023_bib0188","doi-asserted-by":"crossref","first-page":"eaax4063","DOI":"10.1126\/science.aax4063","article-title":"Biological functions of lymphatic vessels","volume":"369","author":"Petrova","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.actbio.2021.06.023_bib0189","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.immuni.2004.11.013","article-title":"The conduit system transports soluble antigens from the afferent lymph to resident dendritic cells in the T cell area of the lymph node","volume":"22","author":"Sixt","year":"2005","journal-title":"Immunity"},{"key":"10.1016\/j.actbio.2021.06.023_bib0190","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1038\/nrd4608","article-title":"From sewer to saviour \u2014 targeting the lymphatic system to promote drug exposure and activity","volume":"14","author":"Trevaskis","year":"2015","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.actbio.2021.06.023_bib0191","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.jconrel.2006.01.006","article-title":"In vivo targeting of dendritic cells in lymph nodes with poly(propylene sulfide) nanoparticles","volume":"112","author":"Reddy","year":"2006","journal-title":"J. Control. Release"},{"key":"10.1016\/j.actbio.2021.06.023_bib0192","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1038\/nature12978","article-title":"Structure-based programming of lymph-node targeting in molecular vaccines","volume":"507","author":"Liu","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.actbio.2021.06.023_bib0193","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.biomaterials.2017.03.047","article-title":"Vaccine nanocarriers: coupling intracellular pathways and cellular biodistribution to control CD4 vs CD8 T cell responses","volume":"132","author":"Rincon-Restrepo","year":"2017","journal-title":"Biomaterials"},{"key":"10.1016\/j.actbio.2021.06.023_bib0194","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.addr.2020.06.003","article-title":"Dawn of lipid nanoparticles in lymph node targeting: potential in cancer immunotherapy","volume":"167","author":"Nakamura","year":"2020","journal-title":"Adv. Drug. Deliv. Rev."},{"key":"10.1016\/j.actbio.2021.06.023_bib0195","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.addr.2016.04.007","article-title":"50 years of oral lipid-based formulations: provenance, progress and future perspectives","volume":"101","author":"Feeney","year":"2016","journal-title":"Adv. Drug. Deliv. Rev."},{"key":"10.1016\/j.actbio.2021.06.023_bib0196","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1002\/jps.21970","article-title":"Biodegradable PLGA based nanoparticles for sustained regional lymphatic drug delivery","volume":"99","author":"Rao","year":"2010","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.actbio.2021.06.023_bib0197","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1002\/eji.200737984","article-title":"Nanoparticles target distinct dendritic cell populations according to their size","volume":"38","author":"Manolova","year":"2008","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.actbio.2021.06.023_bib0198","first-page":"9726","article-title":"Addressing the PEG mucoadhesivity paradox to engineer nanoparticles that \u201cslip\u201d through the human mucus barrier","volume":"47","author":"Wang","year":"2008","journal-title":"Adv. Drug. Deliv. Rev."},{"key":"10.1016\/j.actbio.2021.06.023_bib0199","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/nmat2347","article-title":"Stealth particles give mucus the slip","volume":"8","author":"Cu","year":"2009","journal-title":"Nat. Mater."},{"key":"10.1016\/j.actbio.2021.06.023_bib0200","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1021\/acs.molpharmaceut.9b01182","article-title":"The effect of size and charge of lipid nanoparticles prepared by microfluidic mixing on their lymph node transitivity and distribution","volume":"17","author":"Nakamura","year":"2020","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.actbio.2021.06.023_bib0201","doi-asserted-by":"crossref","first-page":"3909","DOI":"10.1021\/acs.molpharmaceut.8b00370","article-title":"Monitoring translation activity of mRNA-loaded nanoparticles in mice","volume":"15","author":"Rosigkeit","year":"2018","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.actbio.2021.06.023_bib0202","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/S0378-5173(02)00129-1","article-title":"Liposome clearance in mice: the effect of a separate and combined presence of surface charge and polymer coating","volume":"240","author":"Levchenko","year":"2002","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.actbio.2021.06.023_bib0203","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.ijpharm.2005.10.010","article-title":"Opsonization, biodistribution, and pharmacokinetics of polymeric nanoparticles","volume":"307","author":"Owens","year":"2006","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.actbio.2021.06.023_bib0204","doi-asserted-by":"crossref","first-page":"2525","DOI":"10.1021\/ja107583h","article-title":"Physical\u2212chemical aspects of protein corona: relevance to in vitro and in vivo biological impacts of nanoparticles","volume":"133","author":"Monopoli","year":"2011","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.actbio.2021.06.023_bib0205","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.jconrel.2020.03.006","article-title":"Different kinetics for the hepatic uptake of lipid nanoparticles between the apolipoprotein E\/low density lipoprotein receptor and the N-acetyl-d-galactosamine\/asialoglycoprotein receptor pathway","volume":"322","author":"Sato","year":"2020","journal-title":"J. Control. Release"},{"key":"10.1016\/j.actbio.2021.06.023_bib0206","doi-asserted-by":"crossref","first-page":"2424","DOI":"10.1038\/s41467-020-16248-y","article-title":"Synergistic lipid compositions for albumin receptor mediated delivery of mRNA to the liver","volume":"11","author":"Miao","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.actbio.2021.06.023_bib0207","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/j.actbio.2020.02.018","article-title":"Tuning liposome composition to modulate corona formation in human serum and cellular uptake","volume":"106","author":"Yang","year":"2020","journal-title":"Acta Biomater."},{"key":"10.1016\/j.actbio.2021.06.023_bib0208","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1021\/acschembio.0c00003","article-title":"Engineering Caveolae-targeted lipid nanoparticles to deliver mRNA to the lungs","volume":"15","author":"Li","year":"2020","journal-title":"ACS Chem. Biol."},{"key":"10.1016\/j.actbio.2021.06.023_bib0209","doi-asserted-by":"crossref","DOI":"10.1002\/adma.201802373","article-title":"Flexible nanoparticles reach sterically obscured endothelial targets inaccessible to rigid nanoparticles","volume":"30","author":"Myerson","year":"2018","journal-title":"Adv. Mater."},{"key":"10.1016\/j.actbio.2021.06.023_bib0210","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1189\/jlb.0512231","article-title":"The mannose receptor","volume":"92","author":"Martinez-Pomares","year":"2012","journal-title":"J. Leukoc. Biol."},{"key":"10.1016\/j.actbio.2021.06.023_bib0211","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/S0092-8674(00)80693-5","article-title":"Identification of DC-SIGN, a novel dendritic cell\u2013specific ICAM-3 receptor that supports primary immune responses","volume":"100","author":"Geijtenbeek","year":"2000","journal-title":"Cell"},{"key":"10.1016\/j.actbio.2021.06.023_bib0212","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1038\/375151a0","article-title":"The receptor DEC-205 expressed by dendritic cells and thymic epithelial cells is involved in antigen processing","volume":"375","author":"Jiang","year":"1995","journal-title":"Nature"},{"key":"10.1016\/j.actbio.2021.06.023_bib0213","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/S1074-7613(00)80160-0","article-title":"Langerin, a novel C-type lectin specific to langerhans cells, is an endocytic receptor that induces the formation of birbeck granules","volume":"12","author":"Valladeau","year":"2000","journal-title":"Immunity"},{"key":"10.1016\/j.actbio.2021.06.023_bib0214","doi-asserted-by":"crossref","DOI":"10.1155\/2015\/680620","article-title":"Towards targeted delivery systems: ligand conjugation strategies for mrna nanoparticle tumor vaccines","author":"Phua","year":"2015","journal-title":"J. Immunol. Res."},{"key":"10.1016\/j.actbio.2021.06.023_bib0215","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1038\/mt.2015.175","article-title":"Delivery of siRNAs to dendritic cells using DEC205-targeted lipid nanoparticles to inhibit immune responses","volume":"24","author":"Katakowski","year":"2016","journal-title":"Mol. Ther."},{"key":"10.1016\/j.actbio.2021.06.023_bib0216","doi-asserted-by":"crossref","first-page":"980","DOI":"10.3389\/fphar.2018.00980","article-title":"Optimization of the linker length of mannose-cholesterol conjugates for enhanced mRNA delivery to dendritic cells by liposomes","volume":"9","author":"Wang","year":"2018","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.actbio.2021.06.023_bib0217","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/j.nano.2010.12.010","article-title":"Enhancement of dendritic cells transfection in vivo and of vaccination against B16F10 melanoma with mannosylated histidylated lipopolyplexes loaded with tumor antigen messenger RNA","volume":"7","author":"Perche","year":"2011","journal-title":"Nanomedicine"},{"key":"10.1016\/j.actbio.2021.06.023_bib0218","doi-asserted-by":"crossref","first-page":"123","DOI":"10.3390\/vaccines8010123","article-title":"mRNA vaccines encoding the HA protein of Influenza A H1N1 virus delivered by cationic lipid nanoparticles induce protective immune responses in mice","volume":"8","author":"Zhuang","year":"2020","journal-title":"Vaccines"},{"key":"10.1016\/j.actbio.2021.06.023_bib0219","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1038\/s41565-017-0043-5","article-title":"A modular platform for targeted RNAi therapeutics","volume":"13","author":"Kedmi","year":"2018","journal-title":"Nat. Nanotechnol."},{"key":"10.1016\/j.actbio.2021.06.023_bib0220","doi-asserted-by":"crossref","first-page":"4493","DOI":"10.1038\/s41467-018-06936-1","article-title":"Cell specific delivery of modified mRNA expressing therapeutic proteins to leukocytes","volume":"9","author":"Veiga","year":"2018","journal-title":"Nat. Commun."},{"key":"10.1016\/j.actbio.2021.06.023_bib0221","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1023\/A:1018888927852","article-title":"Body distribution of camptothecin solid lipid nanoparticles after oral administration","volume":"16","author":"Yang","year":"1999","journal-title":"Pharm. Res."},{"key":"10.1016\/j.actbio.2021.06.023_bib0222","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.tube.2005.08.009","article-title":"Oral solid lipid nanoparticle-based antitubercular chemotherapy","volume":"85","author":"Pandey","year":"2005","journal-title":"Tuberculosis"},{"key":"10.1016\/j.actbio.2021.06.023_bib0223","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/S0378-5173(02)00080-7","article-title":"Solid lipid nanoparticles (SLN) as ocular delivery system for tobramycin","volume":"238","author":"Cavalli","year":"2002","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.actbio.2021.06.023_bib0224","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.ijpharm.2005.09.007","article-title":"Drug release and permeation studies of nanosuspensions based on solidified reverse micellar solutions (SRMS)","volume":"305","author":"Friedrich","year":"2005","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.actbio.2021.06.023_bib0225","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1002\/jps.2600840415","article-title":"Preparation and structure of a water-in-oil cream containing lipid nanoparticles","volume":"84","author":"de Vringer","year":"1994","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.actbio.2021.06.023_bib0226","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1080\/026520499288690","article-title":"Solid lipid nanoparticles (SLNTM\/LipopearlsTM) a pharmaceutical and cosmetic carrier for the application of vitamin E in dermal products","volume":"16","author":"Dingler","year":"1999","journal-title":"J. Microencapsul."},{"key":"10.1016\/j.actbio.2021.06.023_bib0227","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/S0939-6411(01)00233-8","article-title":"Semisolid SLNTM dispersions for topical application: influence of formulation and production parameters on viscoelastic properties","volume":"53","author":"Lippacher","year":"2002","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.actbio.2021.06.023_bib0228","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/S0939-6411(01)00157-6","article-title":"Bioavailability of diazepam from aqueous-organic solution, submicron emulsion and solid lipid nanoparticles after rectal administration in rabbits","volume":"52","author":"Sznitowska","year":"2001","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.actbio.2021.06.023_bib0229","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.jconrel.2018.07.026","article-title":"Dexamethasone prodrugs as potent suppressors of the immunostimulatory effects of lipid nanoparticle formulations of nucleic acids","volume":"286","author":"Chen","year":"2018","journal-title":"J. Control. Release"},{"key":"10.1016\/j.actbio.2021.06.023_bib0230","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1136\/bmj.321.7271.1237","article-title":"The importance of injecting vaccines into muscle","volume":"321","author":"Zuckerman","year":"2000","journal-title":"BMJ"},{"key":"10.1016\/j.actbio.2021.06.023_bib0231","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.omtn.2021.03.008","article-title":"Functionalized lipid nanoparticles for subcutaneous administration of mRNA to achieve systemic exposures of a therapeutic protein","volume":"24","author":"Davies","year":"2021","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.actbio.2021.06.023_bib0232","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/j.jconrel.2015.08.007","article-title":"Expression kinetics of nucleoside-modified mRNA delivered in lipid nanoparticles to mice by various routes","volume":"217","author":"Pardi","year":"2015","journal-title":"J. Control. Release"},{"key":"10.1016\/j.actbio.2021.06.023_bib0233","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/S0168-3659(99)00007-3","article-title":"Body distribution in mice of intravenously injected camptothecin solid lipid nanoparticles and targeting effect on brain","volume":"59","author":"Yang","year":"1999","journal-title":"J. Control. Release"},{"key":"10.1016\/j.actbio.2021.06.023_bib0234","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1016\/j.addr.2003.12.002","article-title":"Solid lipid nanoparticles for parenteral drug delivery","volume":"56","author":"Wissing","year":"2004","journal-title":"Adv. Drug. Deliv. Rev."},{"key":"10.1016\/j.actbio.2021.06.023_bib0235","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1056\/NEJMoa043540","article-title":"Dose sparing with intradermal injection of influenza vaccine","volume":"351","author":"Kenney","year":"2004","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.actbio.2021.06.023_bib0236","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.3389\/fimmu.2017.01539","article-title":"Induction of robust B cell responses after Influenza mRNA vaccination is accompanied by circulating hemagglutinin-specific ICOS+ PD-1+ CXCR3+ T follicular helper cells","volume":"8","author":"Lindgren","year":"2017","journal-title":"Front. Immunol."},{"key":"10.1016\/j.actbio.2021.06.023_bib0237","doi-asserted-by":"crossref","first-page":"2635","DOI":"10.1016\/j.ymthe.2017.08.006","article-title":"Efficient targeting and activation of antigen-presenting cells in vivo after modified mRNA vaccine administration in rhesus macaques","volume":"25","author":"Liang","year":"2017","journal-title":"Mol. Ther."},{"key":"10.1016\/j.actbio.2021.06.023_bib0238","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.vaccine.2015.10.132","article-title":"A novel lipid nanoparticle adjuvant significantly enhances B cell and T cell responses to sub-unit vaccine antigens","volume":"34","author":"Swaminathan","year":"2016","journal-title":"Vaccine"},{"key":"10.1016\/j.actbio.2021.06.023_bib0239","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1038\/nbt.2612","article-title":"Image-based analysis of lipid nanoparticle\u2013mediated siRNA delivery, intracellular trafficking and endosomal escape","volume":"31","author":"Gilleron","year":"2013","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.actbio.2021.06.023_bib0240","doi-asserted-by":"crossref","first-page":"4333","DOI":"10.1038\/s41467-019-12275-6","article-title":"Linkage between endosomal escape of LNP-mRNA and loading into EVs for transport to other cells","volume":"10","author":"Maugeri","year":"2019","journal-title":"Nat. Commun."},{"key":"10.1016\/j.actbio.2021.06.023_bib0241","doi-asserted-by":"crossref","first-page":"3481","DOI":"10.1038\/emboj.2011.286","article-title":"Endosome maturation","volume":"30","author":"Huotari","year":"2011","journal-title":"EMBO J."},{"key":"10.1016\/j.actbio.2021.06.023_bib0242","doi-asserted-by":"crossref","first-page":"6518","DOI":"10.1093\/nar\/gkw236","article-title":"The delivery of therapeutic oligonucleotides","volume":"44","author":"Juliano","year":"2016","journal-title":"Nucleic. Acids. Res."},{"key":"10.1016\/j.actbio.2021.06.023_bib0243","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1038\/s41434-019-0095-2","article-title":"Inside out: optimization of lipid nanoparticle formulations for exterior complexation and in vivo delivery of saRNA","volume":"26","author":"Blakney","year":"2019","journal-title":"Gene Ther."},{"key":"10.1016\/j.actbio.2021.06.023_bib0244","doi-asserted-by":"crossref","first-page":"3523","DOI":"10.1038\/s41467-020-17409-9","article-title":"Self-amplifying RNA SARS-CoV-2 lipid nanoparticle vaccine candidate induces high neutralizing antibody titers in mice","volume":"11","author":"McKay","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.actbio.2021.06.023_bib0245","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2020.102743","article-title":"Microneedle array delivered recombinant coronavirus vaccines: immunogenicity and rapid translational development","volume":"55","author":"Kim","year":"2020","journal-title":"EBioMedicine"},{"key":"10.1016\/j.actbio.2021.06.023_bib0246","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.ymthe.2019.09.009","article-title":"A Trans-amplifying RNA vaccine strategy for induction of potent protective immunity","volume":"28","author":"Beissert","year":"2020","journal-title":"Mol. Ther."},{"key":"10.1016\/j.actbio.2021.06.023_bib0247","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1038\/s41434-020-00204-y","article-title":"Self-amplifying RNA vaccines for infectious diseases","volume":"28","author":"Bloom","year":"2020","journal-title":"Gene Ther."},{"key":"10.1016\/j.actbio.2021.06.023_bib0248","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1097\/CJI.0b013e31815ce501","article-title":"Results of the first phase I\/II clinical vaccination trial with direct injection of mRNA","volume":"31","author":"Weide","year":"2008","journal-title":"J. Immunother."},{"key":"10.1016\/j.actbio.2021.06.023_bib0249","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1093\/biostatistics\/kxx069","article-title":"Estimation of clinical trial success rates and related parameters","volume":"20","author":"Wong","year":"2019","journal-title":"Biostatistics"},{"key":"10.1016\/j.actbio.2021.06.023_bib0250","unstructured":"Moderna Inc, Moderna announces positive phase 1 results for the first systemic messenger RNA therapeutic encoding a secreted protein (mRNA-1944), https:\/\/investors.modernatx.com\/news-releases\/news-release-details\/moderna-announces-positive-phase-1-results-first-systemic, 2019 (Accessed 13 May 2021)."},{"key":"10.1016\/j.actbio.2021.06.023_bib0251","unstructured":"Moderna Inc, Moderna announces positive interim results from phase 1 cytomegalovirus (CMV) vaccine (mRNA-1647) study and progress toward phase 2 and pivotal trials, https:\/\/investors.modernatx.com\/news-releases\/news-release-details\/moderna-announces-positive-interim-results-phase-1, 2019 (Accessed 13 May 2021)."},{"key":"10.1016\/j.actbio.2021.06.023_bib0252","unstructured":"Moderna Inc, Moderna announces additional positive phase 1 data from cytomegalovirus (CMV) vaccine (mRNA-1647) and first participant dosed in phase 2 study, https:\/\/investors.modernatx.com\/news-releases\/news-release-details\/moderna-announces-additional-positive-phase-1-data, 2020 (accessed 19 February 2021)."},{"key":"10.1016\/j.actbio.2021.06.023_bib0253","unstructured":"Moderna Inc, Moderna announces positive interim phase 1 data for first combination vaccine against the respiratory viruses hMPV and PIV3, https:\/\/investors.modernatx.com\/news-releases\/news-release-details\/moderna-announces-positive-interim-phase-1-data-first, 2019 (Accessed 13 May 2021)."},{"key":"10.1016\/j.actbio.2021.06.023_bib0254","doi-asserted-by":"crossref","first-page":"3326","DOI":"10.1016\/j.vaccine.2019.04.074","article-title":"mRNA vaccines against H10N8 and H7N9 influenza viruses of pandemic potential are immunogenic and well tolerated in healthy adults in phase 1 randomized clinical trials","volume":"37","author":"Feldman","year":"2019","journal-title":"Vaccine"},{"key":"10.1016\/j.actbio.2021.06.023_bib0255","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1080\/21645515.2020.1829899","article-title":"A phase 1, randomized, placebo-controlled study to evaluate the safety and immunogenicity of an mRNA-based RSV prefusion F protein vaccine in healthy younger and older adults","volume":"17","author":"Aliprantis","year":"2021","journal-title":"Hum. Vaccines Immunother."},{"key":"10.1016\/j.actbio.2021.06.023_bib0256","unstructured":"Moderna Inc, Moderna announces clinical progress from its industry-leading mRNA vaccine franchise and continues investments to accelerate pipeline development, https:\/\/investors.modernatx.com\/news-releases\/news-release-details\/moderna-announces-clinical-progress-its-industry-leading-mrna, 2021 (Accessed 13 May 2021)."},{"key":"10.1016\/j.actbio.2021.06.023_bib0257","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1016\/j.vaccine.2020.12.070","article-title":"Proof-of-concept of a low-dose unmodified mRNA-based rabies vaccine formulated with lipid nanoparticles in human volunteers: a phase 1 trial","volume":"39","author":"Aldrich","year":"2021","journal-title":"Vaccine"},{"key":"10.1016\/j.actbio.2021.06.023_bib0258","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1126\/science.abb2507","article-title":"Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation","volume":"367","author":"Wrapp","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.actbio.2021.06.023_bib0259","unstructured":"BioNTech SE, Pfizer Inc, Pfizer and BioNTech achieve first authorization in the world for a vaccine to combat COVID-19, in, https:\/\/investors.biontech.de\/news-releases\/news-release-details\/pfizer-and-biontech-achieve-first-authorization-world-vaccine, 2020 (Accessed 13 May 2021)."},{"key":"10.1016\/j.actbio.2021.06.023_bib0260","unstructured":"Arcturus Therapeutics, Arcturus therapeutics received approval from Singapore Health Sciences Authority to proceed with phase 2 study of ARCT-021 (LUNAR-COV19) vaccine candidate and provides new and updated clinical and preclinical data, https:\/\/www.businesswire.com\/news\/home\/20201228005277\/en\/, 2020 (Accessed 13 May 2021)."},{"key":"10.1016\/j.actbio.2021.06.023_bib0261","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1056\/NEJMoa2035389","article-title":"Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine","volume":"384","author":"Baden","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.actbio.2021.06.023_bib0262","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.1056\/NEJMoa2034577","article-title":"Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine","volume":"383","author":"Polack","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.actbio.2021.06.023_bib0263","unstructured":"National Center for Immunization & Respiratory Diseases, COVID-19 vaccine safety update, https:\/\/www.cdc.gov\/vaccines\/acip\/meetings\/downloads\/slides-2021-01\/06-COVID-Shimabukuro.pdf, 2021 (Accessed 13 May 2021)."},{"key":"10.1016\/j.actbio.2021.06.023_bib0264","unstructured":"National Institutes of Health, NIH begins study of allergic reactions to Moderna, Pfizer-BioNTech COVID-19 vaccines, https:\/\/www.nih.gov\/news-events\/news-releases\/nih-begins-study-allergic-reactions-moderna-pfizer-biontech-covid-19-vaccines, 2021 (Accessed 13 May 2021)."},{"key":"10.1016\/j.actbio.2021.06.023_bib0265","doi-asserted-by":"crossref","unstructured":"A. Muik, A.-K. Wallisch, B. S\u00e4nger, K.A. Swanson, J. M\u00fchl, W. Chen, H. Cai, R. Sarkar, O. T\u00fcreci, P.R. Dormitzer, U. Sahin, Neutralization of SARS-CoV-2 lineage B.1.1.7 pseudovirus by BNT162b2 vaccine-elicited human sera, bioRxiv, (2021) doi:10.1101\/2021.01.18.426984.","DOI":"10.1101\/2021.01.18.426984"},{"key":"10.1016\/j.actbio.2021.06.023_bib0266","doi-asserted-by":"crossref","unstructured":"X. Xie, J. Zou, C.R. Fontes-Garfias, H. Xia, K.A. Swanson, M. Cutler, D. Cooper, V.D. Menachery, S. Weaver, P.R. Dormitzer, P.-Y. Shi, Neutralization of N501Y mutant SARS-CoV-2 by BNT162b2 vaccine-elicited sera, bioRxiv, (2021) doi:10.1101\/2021.01.07.425740.","DOI":"10.1101\/2021.01.07.425740"},{"key":"10.1016\/j.actbio.2021.06.023_bib0267","doi-asserted-by":"crossref","unstructured":"K. Wu, A.P. Werner, J.I. Moliva, M. Koch, A. Choi, G.B.E. Stewart-Jones, H. Bennett, S. Boyoglu-Barnum, W. Shi, B.S. Graham, A. Carfi, K.S. Corbett, R.A. Seder, D.K. Edwards, mRNA-1273 vaccine induces neutralizing antibodies against spike mutants from global SARS-CoV-2 variants, bioRxiv, (2021) doi:10.1101\/2021.01.25.427948.","DOI":"10.1101\/2021.01.25.427948"},{"key":"10.1016\/j.actbio.2021.06.023_bib0268","doi-asserted-by":"crossref","unstructured":"T. Tada, B.M. Dcosta, M. Samanovic-Golden, R.S. Herati, A. Cornelius, M.J. Mulligan, N.R. Landau, Neutralization of viruses with European, South African, and United States SARS-CoV-2 variant spike proteins by convalescent sera and BNT162b2 mRNA vaccine-elicited antibodies, bioRxiv, (2021) doi:10.1101\/2021.02.05.430003.","DOI":"10.1101\/2021.02.05.430003"},{"key":"10.1016\/j.actbio.2021.06.023_bib0269","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1016\/j.chom.2021.03.008","article-title":"SARS-CoV-2 spike variants exhibit differential infectivity and neutralization resistance to convalescent or post-vaccination sera","volume":"29","author":"Kuzmina","year":"2021","journal-title":"Cell. Host. Microbe"},{"key":"10.1016\/j.actbio.2021.06.023_bib0270","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1038\/s41591-021-01270-4","article-title":"Neutralization of SARS-CoV-2 spike 69\/70 deletion, E484K and N501Y variants by BNT162b2 vaccine-elicited sera","volume":"27","author":"Xie","year":"2021","journal-title":"Nat. Med."},{"key":"10.1016\/j.actbio.2021.06.023_bib0271","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1038\/s41586-021-03412-7","article-title":"The CITIID-NIHR BioResource COVID-19 Collaboration","volume":"593","author":"Collier","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.actbio.2021.06.023_bib0272","doi-asserted-by":"crossref","unstructured":"T. Kustin, N. Harel, U. Finkel, S. Perchik, S. Harari, M. Tahor, I. Caspi, R. Levy, M. Leschinsky, S.K. Dror, G. Bergerzon, H. Gadban, F. Gadban, E. Eliassian, O. Shimron, L. Saleh, H. Ben-Zvi, D. Amichay, A. Ben-Dor, D. Sagas, M. Strauss, Y.S. Avni, A. Huppert, E. Kepten, R.D. Balicer, D. Nezer, S. Ben-Shachar, Evidence for increased breakthrough rates of SARS-CoV-2 variants of concern in BNT162b2 mRNA vaccinated individuals, medRxiv, (2021) doi:10.1101\/2021.04.06.21254882.","DOI":"10.1101\/2021.04.06.21254882"},{"key":"10.1016\/j.actbio.2021.06.023_bib0273","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMc2104974","article-title":"Effectiveness of the BNT162b2 Covid-19 vaccine against the B.1.1.7 and B.1.351 variants","author":"Abu-Raddad","year":"2021","journal-title":"New Engl. J. Med."},{"key":"10.1016\/j.actbio.2021.06.023_bib0274","unstructured":"Moderna Inc, Moderna announces positive initial booster data against SARS-CoV-2 variants of concern, https:\/\/investors.modernatx.com\/news-releases\/news-release-details\/moderna-announces-positive-initial-booster-data-against-sars-cov, 2021 (Accessed 13 May 2021)."},{"key":"10.1016\/j.actbio.2021.06.023_bib0275","unstructured":"Moderna Inc, First participants dosed in phase 1 study evaluating mRNA-1283, Moderna's next generation COVID-19 vaccine, https:\/\/investors.modernatx.com\/news-releases\/news-release-details\/first-participants-dosed-phase-1-study-evaluating-mrna-1283, 2021 (Accessed 13 May 2021)."},{"key":"10.1016\/j.actbio.2021.06.023_bib0276","article-title":"Visual inspection of vaccine storage conditions in general practices: a study of 75 vaccine refrigerators","volume":"14","author":"Thielmann","year":"2019","journal-title":"PLoS ONE"},{"key":"10.1016\/j.actbio.2021.06.023_bib0277","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1016\/j.cell.2020.07.024","article-title":"A thermostable mRNA vaccine against COVID-19","volume":"182","author":"Zhang","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.actbio.2021.06.023_bib0278","doi-asserted-by":"crossref","first-page":"e57755","DOI":"10.1371\/journal.pone.0057755","article-title":"Risk in vaccine research and development quantified","volume":"8","author":"Pronker","year":"2013","journal-title":"PLoS ONE"}],"container-title":["Acta Biomaterialia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1742706121003974?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1742706121003974?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T17:40:36Z","timestamp":1761673236000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1742706121003974"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9]]},"references-count":278,"alternative-id":["S1742706121003974"],"URL":"https:\/\/doi.org\/10.1016\/j.actbio.2021.06.023","relation":{},"ISSN":["1742-7061"],"issn-type":[{"value":"1742-7061","type":"print"}],"subject":[],"published":{"date-parts":[[2021,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"From influenza to COVID-19: Lipid nanoparticle mRNA vaccines at the frontiers of infectious diseases","name":"articletitle","label":"Article Title"},{"value":"Acta Biomaterialia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.actbio.2021.06.023","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Acta Materialia Inc. Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}